Holen Sie sich die Stockscreener-App
70.56
0.13%
-0.09
Schlusskurs vom Vortag:
$70.65
Offen:
$70.67
24-Stunden-Volumen:
3.08M
Relative Volume:
0.61
Marktkapitalisierung:
$10.63B
Einnahmen:
$10.73M
Nettoeinkommen (Verlust:
$-455.74M
KGV:
-19.84
EPS:
-3.5569
Netto-Cashflow:
$-502.70M
1W Leistung:
-0.34%
1M Leistung:
+43.85%
6M Leistung:
+130.44%
1J Leistung:
+65.79%
1-Tages-Spanne:
$70.52
$70.98
1-Wochen-Bereich:
$70.42
$71.05
52-Wochen-Spanne:
$21.51
$72.05
Avidity Biosciences Inc Stock (RNA) Company Profile
Firmenname
Avidity Biosciences Inc
Sektor
Branche
Telefon
858-401-7900
Adresse
3020 CALLAN ROAD, SAN DIEGO, CA
Vergleichen Sie RNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
70.56 | 10.65B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Eingeleitet | Roth Capital | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-06-24 | Eingeleitet | Bernstein | Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-06-11 | Eingeleitet | Raymond James | Strong Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-09-24 | Eingeleitet | Goldman | Buy |
| 2024-08-28 | Eingeleitet | Barclays | Overweight |
| 2024-05-03 | Eingeleitet | BofA Securities | Buy |
| 2024-03-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Strong Buy |
| 2021-09-07 | Eingeleitet | Evercore ISI | Outperform |
| 2021-06-17 | Eingeleitet | Needham | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | Cowen | Outperform |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-07 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten
Halper Sadeh LLC Encourages WTRG, RNA, TCBX Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Avidity Biosciences Inc Stock Analysis and ForecastStochastic Oscillator Alerts & Rapid Capital Trading - earlytimes.in
Avidity Biosciences Inc. (RNA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
How Avidity Biosciences Inc. stock trades during market volatilityMarket Rally & Reliable Breakout Forecasts - newser.com
How Avidity Biosciences Inc. stock performs after earnings2025 Market Trends & Daily Growth Stock Investment Tips - newser.com
Key facts: Novartis to Acquire Avidity for $12B; Raises Sales Guidance - TradingView
Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44 - BioSpace
Will Avidity Biosciences Inc. stock deliver long term returns2025 Market Outlook & Long-Term Safe Return Strategies - newser.com
Price action breakdown for Avidity Biosciences Inc.Quarterly Profit Review & Expert Approved Momentum Ideas - newser.com
Is Avidity Biosciences Inc. showing signs of accumulationBreakout Watch & Low Drawdown Momentum Ideas - newser.com
Using AI based signals to follow Avidity Biosciences Inc.Quarterly Portfolio Review & Technical Analysis for Trade Confirmation - newser.com
Will Avidity Biosciences Inc. stock attract more institutional investorsIndex Update & Community Shared Stock Ideas - newser.com
What Wall Street predicts for Avidity Biosciences Inc. stock priceRate Cut & Low Drawdown Trading Techniques - newser.com
What to expect from Avidity Biosciences Inc. in the next 30 daysWeekly Investment Report & Low Drawdown Momentum Ideas - newser.com
Avidity launches managed access program for DMD44 therapy By Investing.com - Investing.com Nigeria
Looking Into Avidity Biosciences Inc's Recent Short Interest - Benzinga
Avidity Biosciences announces U.S. Managed Access Program (MAP) for investigational therapy del-zota in DMD44 - MarketScreener
Avidity Biosciences Announces U.S. Managed Access Program for Investigational Therapy del-zota in DMD44 - Investing News Network
Avidity launches managed access program for DMD44 therapy - Investing.com
Avidity Biosciences (Nasdaq: RNA) launches del-zota MAP in DMD44, plans 2026 BLA filing - Stock Titan
Can Avidity Biosciences Inc. stock deliver sustainable ROEMarket Movement Recap & Safe Entry Momentum Tips - newser.com
Heatmap analysis for Avidity Biosciences Inc. and competitorsJuly 2025 Spike Watch & Low Volatility Stock Recommendations - newser.com
Detecting support and resistance levels for Avidity Biosciences Inc.Watch List & Daily Market Momentum Tracking - newser.com
Can Avidity Biosciences Inc. stock beat market expectations this quarterWeekly Volume Report & Weekly High Conviction Ideas - newser.com
Why Avidity Biosciences Inc. stock attracts global investorsIndex Update & Weekly High Momentum Picks - newser.com
Is Avidity Biosciences Inc. stock ready for breakoutQuarterly Portfolio Summary & Intraday High Probability Alerts - newser.com
Visual analytics tools that track Avidity Biosciences Inc. performanceJuly 2025 Highlights & Low Risk Entry Point Tips - newser.com
Real time alert setup for Avidity Biosciences Inc. performanceRate Hike & Entry Point Strategy Guides - newser.com
Using R and stats models for Avidity Biosciences Inc. forecastingM&A Rumor & Safe Swing Trade Setups - newser.com
Earnings visualization tools for Avidity Biosciences Inc.July 2025 Technicals & Verified Entry Point Signals - newser.com
How Avidity Biosciences Inc. stock benefits from strong dollarJuly 2025 Pullbacks & Weekly Market Pulse Updates - newser.com
Finanzdaten der Avidity Biosciences Inc-Aktie (RNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):